{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-104272","form_type":"8-K","ticker":"ATXI","cik":"0001644963","company_name":"AVENUE THERAPEUTICS, INC.","filed_at":"2023-09-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.666262+00:00","generated_at":"2026-06-10T08:11:27.595702+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Avenue Therapeutics enrolls 8th patient in SBMA trial, triggering 276,652 share issuance to AnnJi","bullets":["Enrolled eighth patient in Phase 1b/2a trial of AJ201 for spinal and bulbar muscular atrophy (SBMA).","Issued 276,652 shares of common stock to AnnJi as Second Tranche Shares under license agreement.","Trial is 12-week, multicenter, randomized, double-blind, targeting ~24 patients; primary endpoint safety/tolerability.","AJ201 activates Nrf1/Nrf2 and enhances androgen receptor degradation; previously paid $3M cash and 831,618 shares."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-104272","json":"https://secwatch.observer/filing/0001104659-23-104272.json","markdown":"https://secwatch.observer/filing/0001104659-23-104272.md","text":"https://secwatch.observer/filing/0001104659-23-104272.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1644963/000110465923104272/0001104659-23-104272-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1644963/000110465923104272/tm2327078d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T08:11:27.595702+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}